Effects of Switching from Depakene to Generic Valproic Acid on Individuals with Mental Retardation
Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can res...
Gespeichert in:
| Veröffentlicht in: | Mental retardation (Washington) 1997-12, Vol.35 (6), p.468-471 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 471 |
|---|---|
| container_issue | 6 |
| container_start_page | 468 |
| container_title | Mental retardation (Washington) |
| container_volume | 35 |
| creator | Vadney, Victor J Kraushaar, Kevin W |
| description | Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can result in substantial cost savings. (Author/DB) |
| doi_str_mv | 10.1352/0047-6765(1997)035<0468:EOSFDT>2.0.CO;2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79503617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ericid>EJ559536</ericid><sourcerecordid>1293636289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-5e0a1cfc65ad5a999871d37e00acb31e98d5e2c64588866e9916554b4eae26773</originalsourceid><addsrcrecordid>eNpdkUtrGzEUhbVIyMPtP2hBUAjNwo4eI2mUhEBwHDclxdA8tkLW3GmUjkeuNJPQf18NNl50dQXn3KvD-RA6o2RCuWBnhBRqLJUUX6nW6pRwcUkKWZ7PFg-3N49XbEIm08UF20NHO-chOk7plRDKKC0O0IEumCiVPELLWV2D6xIONX5495178e0vXMewwjewtr-hBdwFPM8zeoefbbOOIT-una9waPFdW_k3X_W2STivv-Af0Ha2wT-hs7GynQ_tB7RfZxk-bucIPd3OHqffxveL-d30-n7sONXdWACx1NVOClsJq7UuFa24AkKsW3IKuqwEMCcLUZallKA1lUIUywIsMKkUH6GTzd2c8E8PqTMrnxw0jW0h9MkoLQiXdDB--c_4GvrY5myGMs0ll6zU2TXfuFwMKUWozTr6lY1_DSVm4GCGds3Qrhk4mMzBDBzMhoPJBjNdGJYvfd7-1y9XUO3ubCFk_dNGHyreqbPvQmiR0_wDVBCRfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1293636289</pqid></control><display><type>article</type><title>Effects of Switching from Depakene to Generic Valproic Acid on Individuals with Mental Retardation</title><source>MEDLINE</source><source>Education Source</source><source>Periodicals Index Online</source><creator>Vadney, Victor J ; Kraushaar, Kevin W</creator><creatorcontrib>Vadney, Victor J ; Kraushaar, Kevin W</creatorcontrib><description>Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can result in substantial cost savings. (Author/DB)</description><identifier>ISSN: 0047-6765</identifier><identifier>DOI: 10.1352/0047-6765(1997)035<0468:EOSFDT>2.0.CO;2</identifier><identifier>PMID: 9425876</identifier><language>eng</language><publisher>United States: American Association on Mental Retardation, etc</publisher><subject>Adolescent ; Adult ; Aged ; Anticonvulsants - therapeutic use ; Comparative Analysis ; Costs ; Cross-Over Studies ; Depakene ; Drug Therapy ; Drugs, Generic ; Humans ; Intellectual Disability - complications ; Mental Retardation ; Middle Aged ; Outcomes of Treatment ; Seizures ; Seizures - complications ; Seizures - drug therapy ; Valproic Acid ; Valproic Acid - therapeutic use</subject><ispartof>Mental retardation (Washington), 1997-12, Vol.35 (6), p.468-471</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27846,27901,27902</link.rule.ids><backlink>$$Uhttp://eric.ed.gov/ERICWebPortal/detail?accno=EJ559536$$DView record in ERIC$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9425876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vadney, Victor J</creatorcontrib><creatorcontrib>Kraushaar, Kevin W</creatorcontrib><title>Effects of Switching from Depakene to Generic Valproic Acid on Individuals with Mental Retardation</title><title>Mental retardation (Washington)</title><addtitle>Ment Retard</addtitle><description>Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can result in substantial cost savings. (Author/DB)</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Comparative Analysis</subject><subject>Costs</subject><subject>Cross-Over Studies</subject><subject>Depakene</subject><subject>Drug Therapy</subject><subject>Drugs, Generic</subject><subject>Humans</subject><subject>Intellectual Disability - complications</subject><subject>Mental Retardation</subject><subject>Middle Aged</subject><subject>Outcomes of Treatment</subject><subject>Seizures</subject><subject>Seizures - complications</subject><subject>Seizures - drug therapy</subject><subject>Valproic Acid</subject><subject>Valproic Acid - therapeutic use</subject><issn>0047-6765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>HYQOX</sourceid><sourceid>K30</sourceid><recordid>eNpdkUtrGzEUhbVIyMPtP2hBUAjNwo4eI2mUhEBwHDclxdA8tkLW3GmUjkeuNJPQf18NNl50dQXn3KvD-RA6o2RCuWBnhBRqLJUUX6nW6pRwcUkKWZ7PFg-3N49XbEIm08UF20NHO-chOk7plRDKKC0O0IEumCiVPELLWV2D6xIONX5495178e0vXMewwjewtr-hBdwFPM8zeoefbbOOIT-una9waPFdW_k3X_W2STivv-Af0Ha2wT-hs7GynQ_tB7RfZxk-bucIPd3OHqffxveL-d30-n7sONXdWACx1NVOClsJq7UuFa24AkKsW3IKuqwEMCcLUZallKA1lUIUywIsMKkUH6GTzd2c8E8PqTMrnxw0jW0h9MkoLQiXdDB--c_4GvrY5myGMs0ll6zU2TXfuFwMKUWozTr6lY1_DSVm4GCGds3Qrhk4mMzBDBzMhoPJBjNdGJYvfd7-1y9XUO3ubCFk_dNGHyreqbPvQmiR0_wDVBCRfw</recordid><startdate>19971201</startdate><enddate>19971201</enddate><creator>Vadney, Victor J</creator><creator>Kraushaar, Kevin W</creator><general>American Association on Mental Retardation, etc</general><scope>7SW</scope><scope>BJH</scope><scope>BNH</scope><scope>BNI</scope><scope>BNJ</scope><scope>BNO</scope><scope>ERI</scope><scope>PET</scope><scope>REK</scope><scope>WWN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ADABO</scope><scope>BEAJS</scope><scope>HYQOX</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PEXHY</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>SDSKB</scope><scope>~OS</scope><scope>7X8</scope></search><sort><creationdate>19971201</creationdate><title>Effects of Switching from Depakene to Generic Valproic Acid on Individuals with Mental Retardation</title><author>Vadney, Victor J ; Kraushaar, Kevin W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-5e0a1cfc65ad5a999871d37e00acb31e98d5e2c64588866e9916554b4eae26773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Comparative Analysis</topic><topic>Costs</topic><topic>Cross-Over Studies</topic><topic>Depakene</topic><topic>Drug Therapy</topic><topic>Drugs, Generic</topic><topic>Humans</topic><topic>Intellectual Disability - complications</topic><topic>Mental Retardation</topic><topic>Middle Aged</topic><topic>Outcomes of Treatment</topic><topic>Seizures</topic><topic>Seizures - complications</topic><topic>Seizures - drug therapy</topic><topic>Valproic Acid</topic><topic>Valproic Acid - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Vadney, Victor J</creatorcontrib><creatorcontrib>Kraushaar, Kevin W</creatorcontrib><collection>ERIC</collection><collection>ERIC (Ovid)</collection><collection>ERIC</collection><collection>ERIC</collection><collection>ERIC (Legacy Platform)</collection><collection>ERIC( SilverPlatter )</collection><collection>ERIC</collection><collection>ERIC PlusText (Legacy Platform)</collection><collection>Education Resources Information Center (ERIC)</collection><collection>ERIC</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Archive Online Foundation Collection 3 (2022)</collection><collection>Periodicals Archive Online Foundation Collection 3</collection><collection>ProQuest Historical Periodicals</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Periodicals Archive Online Foundation Collection 3.2</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>Periodicals Index Online Segment 43</collection><collection>Periodicals Archive Online Collection 10</collection><collection>MEDLINE - Academic</collection><jtitle>Mental retardation (Washington)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vadney, Victor J</au><au>Kraushaar, Kevin W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><ericid>EJ559536</ericid><atitle>Effects of Switching from Depakene to Generic Valproic Acid on Individuals with Mental Retardation</atitle><jtitle>Mental retardation (Washington)</jtitle><addtitle>Ment Retard</addtitle><date>1997-12-01</date><risdate>1997</risdate><volume>35</volume><issue>6</issue><spage>468</spage><epage>471</epage><pages>468-471</pages><issn>0047-6765</issn><abstract>Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can result in substantial cost savings. (Author/DB)</abstract><cop>United States</cop><pub>American Association on Mental Retardation, etc</pub><pmid>9425876</pmid><doi>10.1352/0047-6765(1997)035<0468:EOSFDT>2.0.CO;2</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0047-6765 |
| ispartof | Mental retardation (Washington), 1997-12, Vol.35 (6), p.468-471 |
| issn | 0047-6765 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79503617 |
| source | MEDLINE; Education Source; Periodicals Index Online |
| subjects | Adolescent Adult Aged Anticonvulsants - therapeutic use Comparative Analysis Costs Cross-Over Studies Depakene Drug Therapy Drugs, Generic Humans Intellectual Disability - complications Mental Retardation Middle Aged Outcomes of Treatment Seizures Seizures - complications Seizures - drug therapy Valproic Acid Valproic Acid - therapeutic use |
| title | Effects of Switching from Depakene to Generic Valproic Acid on Individuals with Mental Retardation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A33%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Switching%20from%20Depakene%20to%20Generic%20Valproic%20Acid%20on%20Individuals%20with%20Mental%20Retardation&rft.jtitle=Mental%20retardation%20(Washington)&rft.au=Vadney,%20Victor%20J&rft.date=1997-12-01&rft.volume=35&rft.issue=6&rft.spage=468&rft.epage=471&rft.pages=468-471&rft.issn=0047-6765&rft_id=info:doi/10.1352/0047-6765(1997)035%3C0468:EOSFDT%3E2.0.CO;2&rft_dat=%3Cproquest_cross%3E1293636289%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1293636289&rft_id=info:pmid/9425876&rft_ericid=EJ559536&rfr_iscdi=true |